Halberd (Halberd) Research & Development : $ Mil (TTM As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Halberd's Research & Development for the six months ended in Jul. 2023 was $0.30 Mil. Halberd does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Jul. 2023.

Halberd Research & Development Historical Data

The historical data trend for Halberd's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Research & Development Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Research & Development

0.91

0.30

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Research & Development	-	0.91	0.30

Halberd Research & Development Calculation

This is the expense the company spent on research and development.

Halberd (OTCPK:HALB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Halberd Research & Development Related Terms

Thank you for viewing the detailed overview of Halberd's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd (Halberd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236